Cargando…

P738: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELODYSPLASTIC SYNDROME: A RETROSPECTIVE COHORT MATCHED STUDY

Detalles Bibliográficos
Autores principales:	Kotselyabina, Polina, Kovalik, Vladislav, Shakhotkina, Alina, Lepik, Kirill, Markelov, Vladislav, Tcvetkov, Nikolay, Kalashnikova, Olga, Moiseev, Ivan, Kulagin, Alexander, Morozova, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429371/ http://dx.doi.org/10.1097/01.HS9.0000969856.62407.38

Ejemplares similares

Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome
por: Tcvetkov, Nikolai, et al.
Publicado: (2020)

P1179: PROGNOSIS OF PATIENTS WITH AGGRESSIVE REFRACTORY B-NHL TREATED WITH GLOFITAMAB IN REAL CLINICAL PRACTICE
por: Fedorova, Liudmila, et al.
Publicado: (2023)

P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila, et al.
Publicado: (2022)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis
por: Moiseev, Ivan, et al.
Publicado: (2022)

High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome
por: Moiseev, Ivan Sergeevich, et al.
Publicado: (2021)

PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
por: Gavrilenko, Andrey, et al.
Publicado: (2023)

P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Fedorova, L., et al.
Publicado: (2022)

PB2423: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH PRIOR INFECTION CAUSED BY THE SARS-COV-2 (COVID-19)
por: Siniaev, Aleksandr, et al.
Publicado: (2023)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
por: Lepik, Kirill V., et al.
Publicado: (2020)

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011)

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Alessandrino, Emilio Paolo, et al.
Publicado: (2013)

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
por: Gusak, Artem, et al.
Publicado: (2021)

738 The Increasing Threat of Group B Streptococcus Infection in Adults
por: Natarajan, Padma, et al.
Publicado: (2014)

Successful treatment of myelodysplastic syndrome and Behcet colitis after allogeneic hematopoietic stem cell transplantation
por: Kook, Min-Ha, et al.
Publicado: (2014)

Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
por: Choi, Eun-Ji, et al.
Publicado: (2018)

Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes
por: Wang, Wei, et al.
Publicado: (2021)

Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Kadri, Yasmine, et al.
Publicado: (2022)

Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?
por: Konuma, Takaaki, et al.
Publicado: (2023)

PT738. Benefits of traditional styles of Japanese diet for mental health
por: Koga, Minori, et al.
Publicado: (2016)

738. A Novel Molecular Diagnostic Assay for Identification of Fungal Pathogens
por: Matzko, Michelle E, et al.
Publicado: (2020)

738 Does A History of Malignancy Lead to Worse Outcomes in Burns?
por: Sljivic, Sanja, et al.
Publicado: (2022)

Micro-Twinning in IN738LC Manufactured with Laser Powder Bed Fusion
por: Megahed, Sandra, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation for Crohn disease complicated with myelodysplastic syndrome: A case report
por: Zhang, Ying, et al.
Publicado: (2020)

Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes
por: Liu, Liu, et al.
Publicado: (2021)

Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation
por: Asano, Takeru, et al.
Publicado: (2014)

Discordant Response of Systemic Mastocytosis Associated With Myelodysplastic Syndrome After Midostaurin and Allogeneic Hematopoietic Stem-cell Transplantation
por: Haas, Marion, et al.
Publicado: (2020)

Minimal Change Disease Secondary to Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndrome
por: Elghawy, Omar, et al.
Publicado: (2022)

Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation
por: Hemsing, Anette Lodvir, et al.
Publicado: (2021)

P1268: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HIGH-RISK MYELODYSPLASTIC NEOPLASMS: A RETROSPECTIVE, SINGLE-CENTER ANALYSIS
por: Christian Schröder, Jan, et al.
Publicado: (2023)

Optimizing Laser Powder Bed Fusion Parameters for IN-738LC by Response Surface Method
por: Vilanova, Mireia, et al.
Publicado: (2020)

738 Access to Burn Care: A 10 Year Perspective of Burn Centers in the U.S.
por: Lovick, Elle, et al.
Publicado: (2023)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Treatment of Crohn’s disease complicated with myelodysplastic syndrome via allogeneic hematopoietic stem cell transplantation: case report and literature review
por: Hu, Changmei, et al.
Publicado: (2014)

Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study
por: Lindholm, C., et al.
Publicado: (2022)

SUN-738 Establishing the Link Between Genetic Variations of Estrogen Receptor 2 and Unexplained Infertility
por: Halassy, Sophia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cfv4i8v1bu8ne95dugjobupba4